Dedicated budgets for medical publication teams 'linked to higher output'
Setting aside a dedicated budget for medical publication tends to be associated with a higher output of manuscripts and abstracts, a report has shown.
In-house medical publication teams that have dedicated budgets in place tend to produce a greater number of manuscripts and abstracts each year, a study has found.
Cutting Edge Information surveyed a number of pharmaceutical medical publications teams and found that more than nine in ten high-output teams had dedicated budgets.
The pharmaceutical intelligence firm observed that companies that commit to the production of medical publications in this way tend to have a higher output of material.
In contrast, just 67 per cent of low-output teams had dedicated budgets in place.
Ryan McGuire, research team leader at Cutting Edge Information, said: "High-output teams exist because their companies have committed to the medical publication group's objectives.
"The foremost and most basic statement of that commitment is to establish a dedicated budget."
Pharmaceutical companies that produce large numbers of medical publications tend to benefit from the greater exposure to doctors and other medical professionals, who may be more likely to prescribe their products.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...